Tải bản đầy đủ - 0 (trang)
Mối liên quan giữa nồng độ TNF-α, IL-1β, IL-6, IL-8, IL-10 với đặc điểm lâm sàng, cận lâm sàng và mức độ nặng ở bệnh nhân VLĐTTCM.

Mối liên quan giữa nồng độ TNF-α, IL-1β, IL-6, IL-8, IL-10 với đặc điểm lâm sàng, cận lâm sàng và mức độ nặng ở bệnh nhân VLĐTTCM.

Tải bản đầy đủ - 0trang

TÀI LIỆU THAM KHẢO

TIẾNG VIỆT

1.



Mai Đình Minh (2016), Khảo sát nồng độ TNF alpha ở bệnh nhân

viêm loét đại trực tràng chảy máu tại khoa Tiêu hóa Bệnh viện Bạch

Mai, Luận văn Thạc sỹ Y học.



2.



Hoàng Gia Lợi (2005), Bệnh học nợi khoa sau đại học "“Xuất hút

tiêu hóa”, Bệnh học nội khoa sau đại học tập II", 42 – 52.



3.



Khúc Đình Minh (2006), Đặc điểm lâm sàng, cận lâm sàng và hiệu

quả điều trị bằng Mesalazine + corticoid ở bệnh nhân viêm loét đại

trực tràng, Luận văn thạc sỹ y học.



4.



Lê Thị Kim Liên (2016), Nghiên cứu lâm sàng, cận lâm sàng và hình

ảnh siêu âm nội soi ở bệnh nhân viêm loét đại trực tràng chảy máu,

Luận văn Bác sĩ chuyên khoa cấp II.



5.



Nguyễn Duy Thắng (2014), "Nhận xét bước đầu trên lâm sàng và nội

soi kết quả điều trị viêm loét đại trực tràng chảy máu thể nhẹ và vừa

bằng Mesalazine (Pentasa)", Tạp chí khoa học Tiêu hoá Việt Nam, 4

(37), pp.



6.



Nguyễn Đạt Anh,CS (2013), "Các xét nghiệm thường quy áp dụng

trong thực hành lâm sàng", Nhà xuất bản Y học.



7.



Nguyễn Quốc Anh,CS (2011), "Viêm loét đại trực tràng chảy máu",

Hướng dẫn chẩn đoán và điều trị bệnh nội khoa, cẩm nang nghiệp vụ

bác sỹ lâm sàng, Nhà xuất bản Y học, pp. 530 - 533.



8.



Nguyễn Thị Thu Hiền (2008), Nghiên cứu đặc điểm lâm sàng và cận lâm

sàng bệnh viêm loét đại trực tràng chảy máu, Luận văn thạc sỹ y học.



9.



Nguyễn Văn Hưng (2011), "Đặc điểm mơ bệnh học bệnh viêm đại

tràng lt", Tạp chí nghiên cứu Y học, 75 (4), pp. 64-71.



10.



Phạm Quang Vinh (2012), "Thiếu máu: Phân loại và điều trị thiếu

máu". Vol. tập 2, Bệnh học nội khoa.



11.



Phạm Văn Dũng (2015), Nghiên cứu đặc điểm lâm sàng xét nghiệm

và các yếu tố (sắt, ferritin, acid folic) ở bệnh nhân viêm loét đại trực

tràng chảy máu, Luận văn thạc sỹ y học.



12.



Vũ Văn Khiên C (2011), "Tổng kết hiệu quả điều trị bệnh viêm loét

đại trực tràng trong 5 năm tại Bệnh viện Trung ương Qn đợi 108",

Tạp chí dược học lâm sàng tập 6-số đặc biệt pp. 124-130.



13.



Jean D. Wilson (2000), "Các nguyên lý y học nội khoa Harrison ". Vol.

3.



14.



Bộ Y tế vụ khoa học và đào tạo (2007), "Xác định cỡ mẫu trong các

nghiên cứu y tế", Nhà xuất bản Y học.



15.



Avdagić N., Babić N (2013), "Tumor necrosis factor-alpha serum level

in assessment of disease activity in inflammatory bowel diaseases",

Med Glas (Zenica), 10(2), pp. 2116.



16.



Baron J., Connell AM., Jones L., et al (1964), "Variation between

observers in describing mucosal appearances in proctocolitis.", BMJ,

pp. 1:89.



17.



Ye BD (2014), "How Useful Are Blood and Stool Biomarkers for

Detecting Subclinical Mucosal Inflammation in Ulcerative Colitis?",

Dig Dis Sci 59, pp. 706–707.



18.



Bentley E., Campbell F., Warren B., et al (2000), "How coud

pathologists improve the intial diagnosis of colitis?", Evidence from an

international workshop. J Clin Pathol, 55, pp. 955-960.



19.



Boldeanu V., Siloşi I., Ghiluşi M., et al (2014), "Invertigation of

inflammatory activity in ulcerative colitis ", Rom J Morphol Embryol,

55 (4), pp. 1345-1351.



20.



Camarillo GF., Carballeda JF (2013), "IL-10 and IL-20-Expressing

Epithelial and Inflammatory Cells are Increased in Patients with

Ulcerative Colitis", J Clin Immunol pp. 640–648.



21.



Chang



S.,



Hudesman



D.,



(2015),



"Disease



monitoring



in



inflammatory bowel disease", World J Gastroenterol 21 (40), pp.

11246-11259.

22.



Childers RE., Childers CV , Vazquez C., et al (2014), "Family

history of inflammatory bowel disease among patients with ulceative

colitis: A systematic review and meta-analysis", Journal of crohn's and

colitis, 8, pp. 1480-1479.



23.



Danese S., Fiocchi C (2011), "Ulcerative Colitis", N Engl J Med 365,

pp. 1713-25.



24.



Danese S., Fiorino G., Biroulet P., et al(2014), "Biological agents for

moderately to severely active ulcerative colitis: a systematic review and

network meta-analysis", Ann Intern Med, 160 (10), pp. 704-711.



25.



Daniel K (2002), "Inflammatory Bowel Disease", N Engl J Med, 347,

pp. 417 – 429.



26.



Daniel S., Shah PK., Whittaker MA (2013), "Cytokine mucosal

expression in ulcerative colitis, the relationship between cytokine release

and disease activity", Journal of Crohn's and Colitis 7,pp. 481-489.



27.



De Dombal FT (1969), "Prognostic value of estimating serum proteins

in cases of ulcerative colitis in remission", Gut, 10, pp. 491-496.



28.



De Dombal FT (1968), "Prognostic value of the serum proteins during

severe attacks of ulcerative colitis", Gut, 9, pp. 144-149.



29.



De



Dombal



FT



(1967),



"Serum



proteins



in



ulcerative



colitis:electrophoretic patterns in the inferior mesenteric artery and

vein", Gut, 8, pp. 482.



30.



Dembic Z (2015), "Cytokines of the Immune System: Interleukins".



31.



Diefenbach K A., Christopher KB (2006), "Pediatric inflammatory

bowel disease", World J Gastroenterol, 12, pp. 3204 – 3212.



32.



Dinić BR., Nagorni A., Katić V., et al (2003), "Clinical Extraintestinal

Manifestations of Ulcerative Colitis ", Medicine and Biology 10 (3),

pp. 139-144.



33.



Dolar ME (1998), "Serum cytokine levels in ulcerative colitis: Their

relationship to disease activity and circulating acute phase reactants",

Turk J Gastroenterol, 9 (4), pp. 370-377.



34.



Eidan A., Iqbal MN., Mahdi LH (2016), "Investigation of Serum

TNF-alpha, TRAF-1, andTRAF-2 in Patients Suffer from Ulcerative

Colitis", Kufa Journal for Nursing Sciences, 6.



35.



Elizabeth R. Paine (2014), "Colonoscopic evaluation in ulcerative

colitis", Gastroenterology Report 2, pp. 161–168.



36.



Falvey JD., Hoskin T., Meijer B., et al (2015), "isease Activity Assessment

in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic

Remission", Inflammatory Bowel Diseases, 21 (4), pp. 824-831.



37.



Feng JS., Guo CC., Luo BT., et al (2015), "Ulcerative colitis with

inflammatory polyposis in a teenage boy: A case report", World J

Gastroenterol, 21 (3), pp. 1044-1048.



38.



Feng JS., Yang Z., Zhu YZ., ,et al (2014), "Serum IL-17 and IL-6

increased accompany with TGF-β and IL-13 respectively in ulcerative

colitis patients", Int J Clin Exp Med 7(12), pp. 5498-5504.



39.



Furfaro F., Bezzio C., Ardizzone S., et al (2015), "Overview of

Biological Therapy in Ulcerative Colitis: Current and Future

Directions", J Gastrointestin Liver Dis, 24, pp. 203 - 213.



40.



Geboes K., Colombel JF., Greenstein A., et al (2008), "Indeterminate

colitis: A review of the concept – What’s in a name? ", Inflamm bowel

Dis, 14, pp. 850–857.



41.



Geboes K., Riddellb R., Ost A., et al (2000), "A repro – ducible

grading scle for histological assess – ment of inflammation in

ulcerative", Gut, 47, pp. 404-409.



42.



Gledhill T., Bodge K (2013), "New and emerging treatments for

ulcerative colitis: a focus on vedolizumad", Biologics, 7, pp. 123-130.



43.



Greenberg GR., Thomson ABR., (2006), "First Principles of

Gastroenterology", Inflammatory bowel disease pp. 307 - 357.



44.



Guidi L., Marzo M., Andrisani G., , et al (2014), "Faecal calprotectin

assay after induction with anti-Tumour Necrosis Factor α agents in

inflammatory bowel disease: Prediction of clinical response and

mucosal healing at one year", Digestives and liver disease, 44 (11), pp.

974-979.



45.



Guo XG., Wang XP (2011), "Ulcerative Colitis-Treatments, Special

populations and the future", Chappter 3: Drug Therapy in Ulcerative

Colitis.



46.



Hoang-Ngoc Tran D., Ha C (2016), "Circulating cathelicidin levels

correlate with mucosal disease activity in ulcerative colitis, risk of

intestinal stricture in Crohn’s disease, and clinical prognosis in

inflammatory bowel disease", BMC Gastroenterology, {published}, pp.



47.



Holtkamp W., Stollberg T., Reis HE (1995), "Serum interleukin 6 is

related to disease activity but not disease specificity in inflammatory

bowel disease", Clin Gastroenterol Hepatol, 20 (2), pp. 1236.



48.



Islam S., Agarwal M., Talukdar AJ., et al (2016), "A Study on

clinical profile of patients with Inflammatory Bowel Disease

", National Journal of medical researhc



49.



6(3).



Iyer SS (2012), "Role of Interleukin 10 Transcriptional Regulation in

Inflammation and Autoimmune Disease", Crit Rev Immunol, 32 (1), pp.

23-63.



50.



J.F M (1985), "Some aspects of the epidemiology of ulcerative colitis",

Gut, 26, pp. 968-974.



51.



Jenkins D., Gallivan S., Dixon MS., et al (1997), "Guidelines for the

initial biopsy diagnosis of suspected chronic idiopathic inflammatory

bowel disease. The British Society of Gastroenterology Initiative", J

Clin Pathol, 50, pp 93-105.



52.



Jiang X, Cui H (2002), "An analysis of 10218 ulcerative colitis cases

in China", World J Gastroenterol, 8 (1), pp. 158–161.



53.



Johnson D., Bayele H., Johnston K., et al (2004), "Tumour necrosis

factor alpha regulates iron transport and transporter expression in

human intestinal epithelial cells", FEBS Lett, 573 (1-3), pp. 195–201.



54. Kaifang Z., Shi L., Xiaoping X., et al (2001), "Clinical significance and

assessment of cytokines in various stages of ulcerative colitis", Journal

of Tongji Medical University, 21 (4), pp. 308–309.

55.



Kareem MA., Omar HM., Amen A., et al (2006), "Correlation

between



inflammatory



markers,



Endoscopic



findings



and



Histopathological Diagnosis in case of ulcerative colitis", AAMJ, 4 (1).

56.



Kasugai S., Chiba T., Suzuki K., et al (2013), "Seri Changes of

Cytokines in Steroid Refractory Ulcerative Colitis Patients Treated with

Tacrolimus", Journal of Gastroenterology and Hepatology Resaerch, 2.



57.



Keshavarzian A, Fusunyan RD., Winship D., et al (1999), "Increased

interleukin8 (IL8) in rectal dialysate from patients with ulcerative

colitis: evidence for a biological role for IL8 in inflammation of the

colon", American Journal of Gastroenterology 94, pp 704-712.



58.



KILIÇ ZMI., Selime AYAZ., ƯZİN Y., et al (2009), "Plasma

transforming growth factor - β1 level in inflammatory bowel disease",

Turk J Gastroenterol, 20 (3), pp. 165-170.



59.



Kim B., Barnett JL., Kleer CG., et al (1999), "Endoscopic and

histological



patchiness



in



treated



ulcerative



colitis",



Am



J



Gastroenterol, 94, pp 3258-62.

60.



Koido S., Ohkusa T., Takakura K., et al (2013), "Clinical

significance of serum procalcitonin in patients with ulcerative colitis",

World J Gastroenterol 19 (45), pp. 8335-8341.



61.



Korolkova



OY.,



Myers



JN.,



Pellom



ST.,



et



al



(2015),



"Chalacterization of Serum Cytokine Profile in Predominantly Colonic

Inflammatory Bowel Disease to Delineate Ulcerative and Crohn,s

Colitides", Clin Med Insights Gastroenterol, 8, pp 29-44.

62.



Krag A., Israelsen H.,   Ryberg BV., et al (2012), "Safety and efficacy

of Profermin



to induce remission in ulcerative colitis", World J



Gastroenterol 18 (15), pp. 1773-1780.

63.



Langan RC, Michael A. Krafczyk., et al (2007), "Ulcerative Colitis:

Diagnosis and Treatment", Am Fam Physician, 76(9), pp. 1323-30-1331.



64.



Levo Y., Wollner S., Fich A (1986), "Serum IgE levels in patients with

inflammatory bowel disease", Ann Allergy, 56 (1), pp 85-7.



65.



Lewis JD., Chuai S., Nessel L., et al (2008), "Use of the Non-invasive

Components of the Mayo Score to Assess Clinical Response in

Ulcerative Colitis", Inflamm bowel Dis, (14(12)), pp. 1660 - 1666.



66.



Liu Z., Zhou K., Tian S., et al (2018), "Ulcerative colitis with

Guillain–Barré syndrome A case report", Medicine (Baltimore), 97

(25), pp. e11013.



67.



Maleki I., Taghvaei T., Barzin M., et al (2015), "Validation of the

Persian version of the inflammatory bowel disease questionnaire

(IBDQ) in ulcerative colitis patients. Caspian J ", Intern Med 2015, 6

(1), pp. 20 - 24.



68.



Mazlam



MZ.,



Hodgson



HJ



(1994),



"Interrelations



between



interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and

in vitro C-reactive protein generation in patients with inflammatory

bowel disease", Gut, 35, pp. 714-714

69.



Meenakshi (2014), "An optimized patient - reported ulcerative colitis

diasease activity measure derived from the Mayo score and the simple

clinical colistis activity index", Inflamm Bowel Dis, 20 (6), pp. 1070-1078.



70.



Michalska C., Tutk W., Szcrepanek M., et al (2016), "Could the

cytokines concentration be a marker of IBD activity and be useful in

evaluation of IBD differentiation? ", Artic le in Polish, 73 (5), pp. 301-4.



71.



Mofarreh MAAI (2013), "Emerging inflammatory bowel disease in

saudi outpatients: A report of 693 cases", ORIGINAL ARTICLE, 19 (1),

pp. 16-22.



72.



Monstada I., Hovde O., Solberg IC., et al (2014), "Clinical course

and prognosis in ulcerative colitis: results from population-based and

observational studies", Ann Gastroenterol, 27 (2), pp. 95-104.



73.



Muñoz FS., Furusho JKW., (2008), "Role of cytokines in inflammatory

bowel disease", World J Gastroenterol, 14(27), pp. 4280-4288.



74.



Műzes G., Lopez A., Tulassay Z., et al (11/2012), "Changes of the

cytokine



profile



in



inflammatory



bowel



diseases",



World



J



Gastroenterol (18(41)), pp. 5848-5861.

75.



Nielsen OH., Gaustadnes M., Horn T (2013), "Tumor Necrosis

Factor Inhibitors for Inflammatory Bowel Disease", N Engl J Med 369,

pp. 754-762.



76.



Olsena T., Cuia G., Goll R.,et al (2007), "Tissue levels of tumor

necrosis factor-alpha correlates with grade of inflammation in untreated

ulcerative colitis", Gastroenterology, 42 (11), pp. 1312-1320.



77.



Ozin Y., Kilic MZY., Nadir I., et al (2009), "Clinical Features of

Ulcerative Colitis and Crohn’s Disease", J Gastrointestin Liver Dis 18,

pp. 157-162.



78.



Park SJ., Cheon JH., Kim WH (2014), "Clinical characteristics and

treatment of inflammatory bowel disease: A comparison of Eastern and

Western perspectives", World J Gastroenterol, 20 (33), pp. 11525–11537.



79.



Petritsch W., Fuchs S., Berghold A., et al (2013), "Incidence of

inflammatory bowel disease in the province of Styria, Austria, from

1997 to 2007: A population-based study", Journal of Crohn's and

Colitis 7,pp. 58–69.



80.



Ponsky T., Hindle A., Sandler A., et al (2007), "Inflammatory Bowel

Disease in the Pediatric Patient", Surgery clinics of North America 87,

pp. 643-658.



81.



Pongprasobchai S., Manatsathit S., Leelakusolvong S., et al (2001),

"Ulcerative colitis in thailand: a clinical study and long term followup", Journal of the Medical Association of Thailand Chotmaihet

thangphaet, 84 (9), pp. 1281-8.



82.



Qureshi M., Abba Z (2015), "Clinical Presentation of Ulcerative

Colitis



in



Pakistani Adults",



Euroasian



Journal



of



Hepato-



Gastroenterology, 5 (2), pp. 127-130.

83.



Rana SV, Sharma S., Jaspreet Kaur., et al (2014), "Relationship of

cytokines, oxidative stress and GI motility with bacterial overgrowth in

ulcerative colitis patients", Journal of Crohn's and Colitis 8,pp. 859–865.



84.



Reinisch W., Sandborn WJ., Hommes DW., et al (2011),

"Adalimumab for induction of clinical remission in moderately to

severely active ulcerative colitis: results of a randomized controlled

trial", Gut, 60, pp. 780-787.



85.



Rosenberg L., Nanda KS., Zenlea T., et al (2013), "Histologic

Markers of Inflammation in Patients with Ulcerative Colitis in Clinical

Remission", Clin Gastroenterol Hepatol, 11 (8), pp. 991-996.



86.



Ross H., Steele SR., Varma M., et al (2014), "Practice Parameters for

the Surgical Treatment of Ulcerative Colitis", Diseases of the Colon &

ReCtum 27 (1), pp. 5–22.



87.



Sandborn W.J., Haens GD., Assche GV., et al (2013), "One-year

maintenance outcomes among patients with moderately-to-severely

active ulcerative colitis who responded to induction therapy with

adalimumab: subgroup analyses from ULTRA2", Aliment Pharmacol

Ther 37, pp. 204-213.



88.



Sato S., Chiba T., Nakamura., et al (2015), "Changes in cytokine

profile may predict therapeutic efficacy of infliximab in patients with

ulcerative colitis", Gastroenterology, 30 (10), pp. 1467-1472.



89.



Seldenrijk CA., Morson BC., Meuwissen SGM., et al (1991),

"Histopathological evaluation of colonic mucosal biopsy specimens in

chronic inflammatory bowel disease: diagnostic implications", Gut, 32,

pp. 1514 - 1520.



90.



Senanayake SM., Fernandopulle ANR., Niriella MA., et al (2013),

"The long-term outcomes of a cohort of Sri Lankan patients with

ulcerative colitis: a retrospective study at two national referral centers

and review of literature", Clin Exp Gastroenterol, 6, pp. 195-200.



91.



Siew C., Tang W., Ching JI., et al (2013), "Incidence and Phenotype

of In fl ammatory Bowel Disease Based on Results From the Asia-Paci

fic Crohn ’ s and Colitis Epidemiology Study", Gastroenterology, 145,

pp. 158-165.



92.



Simian D., Fluxá D., Lubascher J., et al (2016), "Inflammatory bowel

disease: A descriptive study of 716 local chilean patients", Wold J

Gastroenterol, 22 (22), pp. 5267-5275.



93.



Slverberg MS., Fluxá D., Ahmad T., et al (2005), "Toward an

integrated clincal, molecular and sero logical classification of

inflammatory bowel disease: repost of a Working Party of the 2005

Montreal World Congress of Gastroenterology.



", Gastroenterol



19(Suppl A): 5A - 36A, pp.

94.



Solberg IC., Rosenberg J (2013), "Crohn’s disease and ulcerative

colitis: Occurrence, course and prognosis during the first year of

disease in a European population -based inception cohort", Department

of Gastroenterology, Herlev University Hospital, pp.



95.



Song YN (2015), "Efficacy and safety of tumor necrosis factorablockers for ulcerative colitis: A systematic reviewand meta-analysis

of published randomized controlled trials", journal o f food and drug

analysis pp.



96.



Sood A., Amre D., Midha V., et al (2014), "Low hygiene and exposure

to infections may be associated with increased risk for ulcerative colitis

in a North Indian population", Annals of Gastroenterology, 27 (3), pp.

219-223.



Tài liệu bạn tìm kiếm đã sẵn sàng tải về

Mối liên quan giữa nồng độ TNF-α, IL-1β, IL-6, IL-8, IL-10 với đặc điểm lâm sàng, cận lâm sàng và mức độ nặng ở bệnh nhân VLĐTTCM.

Tải bản đầy đủ ngay(0 tr)

×